Helia Judith Pimentel-Gutiérrez

Helia Judith Pimentel-Gutiérrez

Auto-generated profile, based on publicly available information

Helia Judith Pimentel-Gutiérrez

Department of Hematology/Oncology, Charité–Universitätsmedizin Berlin, 13353 Berlin, Germany

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 September 2016 in Oncology Letters
Verified
Journal Article
Closed access
PDF file
HPHelia Judith Pimentel-Gutiérrez
Helia Judith Pimentel-Gutiérrez
LBLucina Bobadilla-Morales
Lucina Bobadilla-Morales
CBCésar Cenobio Barba-Barba
César Cenobio Barba-Barba
COCitlalli Ortega-De-La-Torre
Citlalli Ortega-De-La-Torre
FSFernando Antonio Sánchez-Zubieta
Fernando Antonio Sánchez-Zubieta
ACAlfredo Corona-Rivera
Alfredo Corona-Rivera
Acute lymphoblastic leukemia (ALL) accounts for 30% of all pediatric cancers. Currently available treatments exhibit toxicity and certain patients may develop resistance. Thus, less toxic and chemoresistance‑reversal agents are required. In the present study, the potential effect of curcumin, a component of Curcuma longa, as a pharmacological co‑adjuvant of several chemotherapeutic agents against ALL, including prednisone, 6‑mercaptopurine, dexamethasone, cyclophosphamide, l‑asparaginase, vincristine, daunorubicin, doxorubicin, methotrexate and cytarabine, was investigated in the REH ALL cell line cultures treated in combination with chemotherapeutic agents and curcumin. The results of cell viability, gene expression and activation of NF-κB and caspase 3 indicated that curcumin potentiates the anticancer effects of the aforementioned chemotherapeutic agents in the REH ALL cell line. Following treatment with the above chemotherapeutic agents, curcumin enhanced caspase‑3 activation and downregulated nuclear factor‑kappa B (NF‑κB) activation. Curcumin also downregulated the oxidative stress induced by certain chemotherapies. Notably, curcumin did not affect the gene expression of cell survival proteins such as B‑cell lymphoma (Bcl)‑2, Bcl‑extra large, survivin, c‑Myc and cyclin D1, which are regulated by the NF‑κB transcription factor. In conclusion, curcumin has the potential to improve the effect of chemotherapeutic agents against ALL.

13 July 2020 in Cancers
Verified
Journal Article
Open access
PDF file
AGAnton Gauert
Anton Gauert
NONadine Olk
Nadine Olk
HPHelia Pimentel-Gutiérrez
Helia Pimentel-Gutiérrez
KAKathy Astrahantseff
Kathy Astrahantseff
LJLasse Jensen
Lasse Jensen
AHAnja Heeren-Hagemann
Anja Heeren-Hagemann
Only half of patients with relapsed B-cell precursor (BCP) acute lymphoblastic leukemia (ALL) currently survive with standard treatment protocols. Predicting individual patient responses to defined drugs prior to application would help therapy stratification and could improve survival. With the purpose to aid personalized targeted treatment approaches, we developed a human–zebrafish xenograft (ALL-ZeFiX) assay to predict drug response in a patient in 5 days. Leukemia blast cells were pericardially engrafted into transiently immunosuppressed Danio rerio embryos, and engrafted embryos treated for the test case, venetoclax, before single-cell dissolution for quantitative whole blast cell analysis. Bone marrow blasts from patients with newly diagnosed or relapsed BCP-ALL were successfully expanded in 60% of transplants in immunosuppressed zebrafish embryos. The response of BCP-ALL cell lines to venetoclax in ALL-ZeFiX assays mirrored responses in 2D cultures. Venetoclax produced varied responses in patient-derived BCP-ALL grafts, including two results mirroring treatment responses in two refractory BCP-ALL patients treated with venetoclax. Here we demonstrate proof-of-concept for our 5-day ALL-ZeFiX assay with primary patient blasts and the test case, venetoclax, which after expanded testing for further targeted drugs could support personalized treatment decisions within the clinical time window for decision-making.

7 March 2018 in Oncology Letters
Verified
Journal Article
Closed access
PDF file
BGBetsy Gonz�Lez‑Quezada
Betsy Gonz�Lez‑Quezada
USUriel Francisco Santana‑Bejarano
Uriel Francisco Santana‑Bejarano
ACAlfredo Corona‑Rivera
Alfredo Corona‑Rivera
HPHelia Pimentel‑Guti�Rrez
Helia Pimentel‑Guti�Rrez
RSRoc�O Silva‑Cruz
Roc�O Silva‑Cruz
VMVíctor Manuel Maciel‑Gutiérrez
Víctor Manuel Maciel‑Gutiérrez
Colorectal cancer (CRC) is the fourth leading worldwide cause of cancer‑associated mortalities. Nuclear factor‑κB (NF‑κB) is a transcriptional regulator of multiple genes associated with CRC. Tumor tissue were compared with normal adjacent mucosa from 30 sporadic patients with CRC were investigated. A total of 8 non‑CRC patients were analyzed as a control group. In the present study, the protein expression of NF‑κB/p65 was detected by immunohistochemistry, and the gene expression profiles of cyclin D1 (CCND1), prostaglandin‑endoperoxide synthase 2, vascular endothelial growth factor A, matrix metallopeptidase 9, BCL2 apoptosis regulator (BCL2), BCL2 like 1, nitric oxide synthase 2, tumor necrosis factor and arachidonate lipoxygenase were detected by reverse transcription‑quantitative polymerase chain reaction. NF‑κB/p65 and genes expression profiles were classified according to tumor-node-metastasis (TNM) clinicopathological parameters, followed by statistical analysis. Higher protein expression of NF‑κB/p65 in the cytoplasm of tumor tissues compared with adjacent normal mucosa was reported; this increment was positively associated with all clinicopathological parameters, except for tumor localization site. The selected genes demonstrated a diverse associative pattern when analyzed with clinicopathological parameters. CCND1 was positively associated with all TNM parameters and BCL2 was negatively associated with all TNM parameters, thus indicating their importance as strong molecular biomarkers for CRC. According to these results, not all selected genes regulated by NF‑κB/p65 show increased expression during CRC development, whereas the transcription factor did. The present study suggests that NF‑κB/p65 overexpression is necessary for CRC establishment and progression, but its transcriptional activity is not sufficient to regulate all target genes in CRC. NF‑κB/p65 and the gene expression profiles reported in the present study may be therapeutically useful. Considering the heterogeneity of the disease, the particular evaluation of these molecules may allow for the selection of proper diagnosis, treatment and follow‑up for patients with sporadic CRC.

31 January 2015 in Molecular Cytogenetics
Verified
Journal Article
Open access
PDF file
LBLucina Bobadilla-Morales
Lucina Bobadilla-Morales
HPHelia J Pimentel-Gutiérrez
Helia J Pimentel-Gutiérrez
SGSergio Gallegos-Castorena
Sergio Gallegos-Castorena
JPJenny A Paniagua-Padilla
Jenny A Paniagua-Padilla
COCitlalli Ortega-De-La-Torre
Citlalli Ortega-De-La-Torre
ACAlfredo Corona-Rivera
Alfredo Corona-Rivera
Here we present a male patient with acute myeloid leukemia (AML) initially diagnosed as M5 and with karyotype 46,XY. After induction therapy, he underwent a HLA-matched allogeneic hematopoietic stem cell transplantation, and six years later he relapsed as AML M1 with an abnormal karyotype //47,XX,+10[2]/47,XX,+11[3]/48,XX,+10,+11[2]/46,XX[13]. Based on this, we tested the possibility of donor cell origin by FISH and molecular STR analysis. We found no evidence of Y chromosome presence by FISH and STR analysis consistent with the success of the allogeneic hematopoietic stem cell transplantation from the female donor. FISH studies confirmed trisomies and no evidence of MLL translocation either p53 or ATM deletion. Additionally 28 fusion common leukemia transcripts were evaluated by multiplex reverse transcriptase-polymerase chain reaction assay and were not rearranged. STR analysis showed a complete donor chimerism. Thus, donor cell leukemia (DCL) was concluded, being essential the use of cytological and molecular approaches. Pediatric DCL is uncommon, our patient seems to be the sixth case and additionally it presented a late donor cell leukemia appearance. Different extrinsic and intrinsic mechanisms have been considered to explain this uncommon finding as well as the implications to the patient.